Lumentum stock whipsaws as Wall Street lifts targets again ahead of Feb. 3 earnings
22 January 2026
1 min read

Lumentum stock whipsaws as Wall Street lifts targets again ahead of Feb. 3 earnings

New York, January 22, 2026, 11:21 EST — Regular session

Lumentum Holdings Inc shares dipped 0.5% to $360.72 late Thursday morning, following a session range from $350.38 up to $391.24.

The laser and optical components maker is quickly turning into a key indicator for data-center network spending, driven by cloud providers routing more traffic over faster connections to support AI server clusters.

The recent flurry of activity coincides with analysts repeatedly adjusting their price targets—brokers’ forecasts for a stock’s value over the next year—in significant jumps, despite the shares having already surged sharply.

Stifel boosted its price target on Lumentum to $400 from $220, maintaining a Buy rating. The firm highlighted a “step-function increase in networking intensity” driven by newer AI systems ramping up data-center traffic. It also noted “positively biased estimate revisions” for Lumentum, along with peers Ciena and Coherent, even as valuations hit multi-year highs. 1

Christopher Rolland at Susquehanna boosted his price target sharply, from $230 to $420, while keeping a positive rating, a report on GuruFocus showed. 2

Rolland said management sees 2026 shaping up as a “breakout year” for laser chip shipments, driven by Lumentum’s ramp-up of indium phosphide device capacity. Indium phosphide, a semiconductor material, is key to certain high-speed laser chips. 3

Earlier this week, Aletheia Capital raised its price target for Lumentum to $500 from $330, maintaining a Buy rating. The firm pointed to stronger demand for electro-absorption modulated lasers (EMLs), which are key components in high-speed optical links. Aletheia also noted that risks around the supply of indium phosphide substrates “appear limited,” referencing inventory levels at suppliers like JSR and Sumitomo. 4

Aletheia’s action sparked about a 10% intraday jump on Tuesday, fueling the stock’s recent swings following a steep climb that brought it close to its 52-week high. 5

A recent regulatory filing included a brief note: a Form 4 revealed that chief accounting officer Matthew Joseph Sepe had 563 shares withheld to meet tax obligations on vesting restricted stock units, valued at $343.27 each. 6

The broader AI-networking basket showed mixed results Thursday. Coherent gained roughly 0.8%, but Ciena dropped around 1.3%.

Yet the stock has climbed past the average analyst target price tracked by MarketScreener, a position that leaves little room for error. Even minor setbacks—like a drop in data-center orders or hiccups in laser capacity growth and yields—could turn Thursday’s volatility into a more pronounced sell-off. 7

Lumentum is set to release its fiscal second-quarter results after the market closes on Feb. 3, followed by a webcast at 5 p.m. ET. Investors will focus on demand trends for high-speed optics, pricing developments, and how quickly production ramps are progressing. 8

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
JPMorgan Chase stock rises as Trump’s 10% credit-card cap plan keeps banks on edge
Previous Story

JPMorgan Chase stock rises as Trump’s 10% credit-card cap plan keeps banks on edge

Why P&G stock is up today: PG shares climb after Procter & Gamble holds outlook
Next Story

Why P&G stock is up today: PG shares climb after Procter & Gamble holds outlook

Go toTop